EGFR and central nervous system cancer: In the Li et al’s study examining 57 IDH-mutant GBM, 7 (12.3%) had EGFR amplification.7 Of these, only three cases (40%) had a glioma methylator (G-CIMP) high phenotype typically found in IDH-mutant grade 4 tumors with more favorable prognosis (Table 1).